Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free NBIX Stock Alerts

Neurocrine Biosciences (NBIX) News Today

Neurocrine Biosciences logo
$174.10 -3.01 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$174.09 -0.01 (-0.01%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Why Is Neurocrine Biosciences Down Today?

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is trading lower as investors digest a mix of analyst updates and insider selling.

  • Positive Sentiment: Truist Financial raised its price target on Neurocrine Biosciences to $200 from $155 and reiterated a buy rating, signaling confidence in further upside for the stock. Benzinga report on Truist price target increase
  • Neutral Sentiment: BMO Capital Markets also lifted its price target on Neurocrine Biosciences to $170 from $144, but kept a market perform rating, suggesting a more cautious view despite the higher valuation estimate. Benzinga report on BMO price target increase
  • Negative Sentiment: Two insiders sold shares in recent transactions, including Darin Lippoldt and Ingrid Delaet, which can create concern about management’s near-term outlook even though the sales were made under pre-arranged 10b5-1 plans. Article on Darin Lippoldt sale Article on Ingrid Delaet sale

Overall, NBIX appears to be getting some analyst support, but the insider selling is likely weighing on sentiment and helping explain why the stock is down.

Posted 1h agoAI Generated. May Contain Errors.

NBIX Latest News

Ingrid Delaet Sells 4,367 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ingrid-delaet-sells-4367-shares-of-neurocrine-biosciences-nasdaqnbix-stock-2026-07-13/
Darin Lippoldt Sells 10,000 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/darin-lippoldt-sells-10000-shares-of-neurocrine-biosciences-nasdaqnbix-stock-2026-07-13/
Neurocrine Biosciences (NASDAQ:NBIX) Given New $200.00 Price Target at Truist Financial
July 13 at 12:35 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurocrine-biosciences-nasdaqnbix-given-new-20000-price-target-at-truist-financial-2026-07-13/
BMO Capital Markets Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock
July 13 at 9:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bmo-capital-markets-forecasts-strong-price-appreciation-for-neurocrine-biosciences-nasdaqnbix-stock-2026-07-13/
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $488,663.98 in Stock
July 12 at 11:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30894474
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $607,316.57 in Stock
July 12 at 11:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30894458
Candriam S.C.A. Cuts Holdings in Neurocrine Biosciences, Inc. $NBIX
July 12 at 10:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-candriam-sca-cuts-holdings-in-neurocrine-biosciences-inc-nbix-2026-07-12/
Ingrid Delaet Sells 2,737 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
July 10 at 6:06 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-07-10/
Ingrid Delaet Sells 2,737 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
July 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ingrid-delaet-sells-2737-shares-of-neurocrine-biosciences-nasdaqnbix-stock-2026-07-09/
Ingrid Delaet Sells 3,401 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
July 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ingrid-delaet-sells-3401-shares-of-neurocrine-biosciences-nasdaqnbix-stock-2026-07-09/
Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $1,507,145.76 in Stock
July 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-neurocrine-biosciences-nasdaqnbix-insider-sells-150714576-in-stock-2026-07-09/
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results-302822071.html
Why Crinetics Stock Soared 99% This Week
July 9, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/07/09/why-crinetics-stock-soared-99-this-week/?utm_source=snapi
Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs
July 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-stock-looks-021409272.html
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-starts-phase-211652241.html
Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/neurocrine-biosciences-nbix-could-8-221509842.html
Darin Lippoldt Sells 9,800 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
July 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30874421
Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia
July 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-nbix-reports-clinically-meaningful-213254990.html
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
July 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-initiates-phase-2-study-of-crinecerfont-in-pediatric-patients-under-4-years-old-with-classic-congenital-adrenal-hyperplasia-302816226.html
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells 200 Shares of Stock
July 1, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-07-01/
Bull of the Day: Neurocrine Biosciences (NBIX)
June 30, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/bull-day-neurocrine-biosciences-nbix-080000514.html
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed?
June 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-6-5-120654054.html
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype
June 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-unveils-crenessity-110758732.html
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now
June 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/neurocrine-biosciences-nbix-high-growth-nasdaq-stocks-to-buy-now-1790894/
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now
June 27, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/neurocrine-biosciences-nbix-high-growth-stocks-to-buy-right-now-1790218/
5 High Growth Stocks to Buy Right Now
June 25, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-high-growth-stocks-to-buy-right-now-1787942/
Pacer Advisors Inc. Purchases 16,257 Shares of Neurocrine Biosciences, Inc. $NBIX
June 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pacer-advisors-inc-purchases-16257-shares-of-neurocrine-biosciences-inc-nbix-2026-06-23/
Perceptive Advisors LLC Sells 119,000 Shares of Neurocrine Biosciences, Inc. $NBIX
June 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-sells-119000-shares-of-neurocrine-biosciences-inc-nbix-2026-06-18/
Boone Capital Management LLC Sells 14,599 Shares of Neurocrine Biosciences, Inc. $NBIX
June 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-boone-capital-management-llc-sells-14599-shares-of-neurocrine-biosciences-inc-nbix-2026-06-18/
Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurocrines-valbenazine-huntington-study-completion-signals-next-phase-for-nbix-investors?utm_source=marketbeat.com&utm_medium=referral
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soleno-therapeutics-presents-new-vykat-xr-diazoxide-choline-data-at-endo-2026-demonstrating-meaningful-and-durable-improvements-in-hyperphagia-and-behavioral-symptoms-in-prader-willi-syndrome-following-randomized-withdrawal-per-302799792.html
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-first-retrospective-case-series-of-crenessity-crinecerfont-in-patients-with-classic-congenital-adrenal-hyperplasia-due-to-11hydroxylase-deficiency-at-endo-2026-302799772.html
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
June 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/neurocrine-biosciences-inc-nbix-good-145527713.html
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
June 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-neurocrine-biosciences-inc-nbix-a-good-stock-to-buy-now-1781859/
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improved-growth-measures-in-pediatric-patients-with-classic-congenital-adrenal-hyperplasia-at-endo-2026-302799743.html
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026-302799744.html
Entropy Technologies LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
June 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-entropy-technologies-lp-makes-new-investment-in-neurocrine-biosciences-inc-nbix-2026-06-15/
Ieq Capital LLC Raises Position in Neurocrine Biosciences, Inc. $NBIX
June 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ieq-capital-llc-raises-position-in-neurocrine-biosciences-inc-nbix-2026-06-13/
Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Director Sells 25,000 Shares of Stock
June 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-06-10/
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
June 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913352-neurocrine-biosciences-inc-nbix-presents-at-goldman-sachs-47th-annual-global-healthcare
Leslie Norwalk Sells 1,250 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
June 9, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-06-09/
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-clinically-meaningful-response-data-on-treatment-of-tardive-dyskinesia-reinforcing-the-efficacy-of-ingrezza-valbenazine-capsules-across-a-broad-range-of-patients-302794193.html
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-data-highlighting-functional-and-socio-emotional-improvements-with-ingrezza-valbenazine-capsules-in-individuals-with-tardive-dyskinesia-and-intellectual-and-developmental-disabilities-302793148.html
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $5,770,298.14 in Stock
June 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-06-05/
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
June 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rbc-capital-raises-price-target-164953724.html
Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst
June 3, 2026  |  quiverquant.comQ
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
June 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-twoyear-crenessity-crinecerfont-data-on-key-clinical-and-patientreported-outcome-measures-at-endo-2026-302789246.html
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $354,321.31 in Stock
June 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-06-03/
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
June 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4911078-neurocrine-biosciences-inc-nbix-presents-at-46th-annual-william-blair-growth-stock-conference
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $1,710,830.00 in Stock
May 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbix-insider-buying-and-selling-2026-05-30/
Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBIX Media Mentions By Week

NBIX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NBIX
News Sentiment
▼
0.55

0.87
▲
Average
Medical
News Sentiment

NBIX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NBIX Articles
This Week
▼
25

7
▲
NBIX Articles
Average Week

Get the Latest News and Ratings for NBIX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:NBIX) was last updated on 7/13/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel